Medicenna Reports Updated Data From ABILITY-1 Trial
In This Article:
Medicenna Therapeutics (MDNA) on Thursday said updated and promising clinical data from its Phase 1/
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Terms and Privacy Policy